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Abstract
The novel coronavirus disease (COVID-19) outbreak started in December 2019 in Wuhan, China, caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The CT image is used to assess the disease progress,
whereas the continued two times of negative results from SARS-CoV-2 nucleic acid detection had been considered
as a criterion for ending antiviral treatment. We compared the two COVID-19 cases with similar backgrounds and
CT image repeated intervals under treatment. Our report highlighted the unsynchronized expression in the changes
of CT image and nucleic acid detection in COVID-19, and lasting positive nucleic acid test result in patients
recovered from pneumonia. It may be contributed to recognize the disease and improve prevention.
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Introduction
The novel coronavirus disease (COVID-19) outbreak
started in December 2019 in Wuhan, China, caused by
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [1, 2]. The Huanan seafood wholesale market in
Wuhan, where is highly suspected as the source place of
COVID-19 [3]. It has spread rapidly in China and mul-
tiple other countries [1, 4]. Over 70,000 COVID-19 cases
had been confirmed until Feb 18. 2020 [5]. The CT
image is used to assess the disease progress, whereas the
continued two times of negative results from SARS-
CoV-2 nucleic acid detection had been considered as a
criterion for ending antiviral treatment. We compared
the two COVID-19 cases with similar backgrounds and
CT image repeated intervals under treatment. Our
report highlighted the unsynchronized expression in the
changes of CT image and nucleic acid detection in
COVID-19, and showed the suspected SARS-CoV-2 car-
rier. It may be contributed to recognize the disease and
improve prevention.
Case 1 description
A 24-year-old man enrolled in his hometown hospital
on Jan 22. 2020 (about 1260 km far from Wuhan),
China, due to a 7-day history of mild fever, dry coughs,
and weakness of unknown cause. He had been lived in
Wuhan since July 2019. Fourteen days before his clinical
symptom appeared, he had visited the seafood wholesale
market in Wuhan. Also, he reported that he contacted
with other respiratory patients with fever in Wuhan. He
traveled home from Wuhan, 2 days before his presenta-
tion to the hospital. At admission (day 1), the patient re-
ported his symptom was very mild, and his body
temperature was 37.6 °C (99.7 °F), whereas coarse breath
sounds of both lungs were heard at auscultation. The re-
sults of laboratory tests indicated normal white blood
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cell count: 5.24 × 109/L. The neutrophils count declined
to 46.7%, whereas C-reactive protein (CRP) was up to
11.8 mg/L. Unenhanced chest computed tomography
(CT) showed multiple patchy shadows in the lower lobe
of both lungs (Fig. 1). The SARS-CoV-2 nucleic acid de-
tection of the patient’s throat swab was positive (Fig. 1).
Thus, the patient was diagnosed as COVID-19. After re-
ceived a day treatment with interferon inhalation (1,000,
000 IU, 3/day) and azithromycin (0.5 g, 1/day), his body
temperature was declined to normal 36.7 °C (98.1 °F).
On day 3 from admission (day 3), the 1st repeated chest
CT showed the infection range was slightly reduced in
the medial segment of the right middle lobe and the dor-
sal segment of the left lower lobe (Fig. 1). On day 8, the
2nd repeated chest CT image showed the infection range
was reduced when compared to the previous one (Fig.
1), and CRP levels was reduced to 1.3 mg/L. On day 10,
the patient had less cough, and body temperature has
slighter increased, but still in normal range, whereas the
2nd nucleic acid in throat swab was still positive. Thus,
it’s added another antiviral medicine as lopinavir (50
mg)/ritonavir (200 mg) (2 tablets, 2 times/day) and
stopped to use azithromycin from day 10 in the treat-
ment. On day 12, the patient reported no clinical symp-
tom, and the repeated chest CT image showed no
infection in the lung (Fig. 1). On day 15, patients re-
ceived the 3rd detection of nucleic acid in throat swab, it
was still positive (Fig. 1). On day 16, the 4th result of nu-
cleic acid in throat swab changed to negative, whereas it
was positive in sputum (Fig. 1), thus continued the anti-
viral treatment with interferon inhalation and lopinavir/
ritonavir. On day 19, the 5th result of nucleic acid in
sputum was still positive (Fig. 1). On day 22, the nucleic
acid in sputum changed to negative, whereas the result
back to positive on day 24 (Fig. 1). The treatment con-
tinued. Finally, the nucleic acid detection result was
changed to negative on day 29 and day 31 (Fig. 1). The
patient was discharged from hospital on day 32.
Case 2 description
A 29-year-old man enrolled in his hometown hospital on
Jan 22, 2020 (about 1250 km far from Wuhan), due to a 3-
day history of very mild fever and cough of unknown cause.
He had been lived in Wuhan since March 2019, and con-
tacted to the other patients with fever in Wuhan. He trav-
eled home from Wuhan, 1 day before his presentation to
the hospital. The patient reported mild symptoms at admis-
sion, since his body temperature was 37.4 °C (99.3 °F),
whereas coarse breath sounds of both lungs were heard at
auscultation. Laboratory tests indicated leucopenia as white
blood cell count was declined to 3.38 × 109/L. The white
blood cell differential count showed 72.8% as neutrophils,
whereas CRP and erythrocyte sedimentation rate (ESR) was
elevated to 9.8mg/L and 15mm/h, respectively. The unen-
hanced chest CT image showed multiple patchy shadows
in lower lobe of both lungs (Fig. 1). The SARS-CoV-2 nu-
cleic acid in throat swab was detected as positive. Thus, the
patient was diagnosed as of COVID-19 pneumonia. Since
Fig. 1 The summary of two COVID-19 cases
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admission (day 1), the patients received the antiviral treat-
ment with interferon inhalation (5,000,000 IU, 2 times/day)
and lopinavir (50mg)/ritonavir (200mg) (2 tablets, 2 times/
day), the antibacterial treatment with ceftazidime (2.0 g, 2
times/day), and the anti-inflammation treatment with pred-
nisone (30mg, 1time/day). On day 3, the body temperature
declined to normal 36.3 °C (97.3 °F) and no cough. On day
8 and day 10, SARS-CoV-2 nucleic acid in throat swab
were shown the negative at that two time, and the repeated
chest CT image showed that the infection range was de-
clined a lot (Fig. 1). On day 12, the infection still showed in
peripheral lung, but very little (Fig. 1), thus the patient was
discharged from hospital. At Feb 18, the CT image of 1st
follow-up showed that no infection in his lung (Fig. 1).
Discussion
The main finding is the unsynchronized changes in the
CT image and SARS-CoV-2 nucleic acid detection in
the two imported COVID-19 cases. Importantly, we
highlight the need for evaluating the suspected virus car-
riers even after the recovery from pneumonia, who may
be asymptomatic with no positive result in laboratory
test. The PCR positive result in the 1st young male pa-
tient lasted nearly 20 days after his pneumonia recovery,
suggested a proportion of recovered patients still may be
asymptomatic virus carriers. When SARS-CoV-2 enters
humans, the interplay between virus and host antiviral
defence is a governed factor for outcome of infection.
Asymptomatic carriers might arise when host antiviral
defence is either strong or decoupled, thus asymptom-
atic shedding might occur when the immune response
effectively limits but could not enough to completely
block SARS-CoV-2 replication [6]. Thus, the continued
treatment and isolated is needed, since the risk of trans-
mitting to others still exist. On the other hand, it is the
need to evaluation the effect of the long-time antiviral
treatment and side effect, especially for positive SARS-
CoV-2 nucleic acid patient without any pneumonia. The
unsynchronized result of nucleic acid detection between
throat and sputum sample were shown in the 1st patient
in our study. First patient showed the virus PCR-
negative throat swab on day 16, whereas the result in
sputum was continued to be positive until day 24. Thus,
we supposed that the different viral load shown between
lower respiratory tract than upper respiratory tract.
Hase. et al. study reported that a COVID-19 case diag-
nosed by PCR-positive lower respiratory specimen, but
with PCR-negative throat swabs [7]. Although the know-
ledge of viral loads in COVID-19 is limited, the high
viral loads of lower respiratory tract specimens had been
reported in severe acute respiratory syndrome (SARS)
and Middle East respiratory syndrome (MERS) [8, 9].
Our results not only confirmed the necessary of multiple
times test in COVID-19, but also highly recommended
to use multitype samples for the disease evaluation, es-
pecially lower airway. To collect the induced sputum
may be recommended for the patients with dry cough or
no symptom. We also noticed that the unsynchronized
expression could also show in the diagnosis stage. In our
cases, the patient had very less symptom, whereas the
CT image showed a clearly infection. This unsynchro-
nized expression may help clinician to arrange the exam-
ination plan for suspected COVID-19 patient. The
choice of antiviral medicine for COVID-19 is still con-
troversial, especially no specific anti-SARS-CoV-2 medi-
cine is available. However, we noticed that the 2nd
patient got quicker recovery compared to the 1st patient,
which may relate to the use of double antiviral medi-
cines at early stage. Olfactory disturbance or taste dis-
order was reported in COVID-19 patients [10], and
these symptoms did not been reported by our patients at
hospital or follow-up. The study was limited to a small
number of patients, which could not identify the repre-
sentative and generalizable in COVID-19.
Conclusion
The unsynchronized changes in the CT image and
SARS-CoV-2 nucleic acid detection in the two imported
COVID-19 cases. Lasting positive nucleic acid test result
shown in patients recovered from COVID-19. Our re-
port would be contributed to aid clinicians in a more
personalized management.
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